Enrolling by invitationPHASE1, PHASE2NCT06811025

Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis

Studying Central nervous system tuberculosis

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Beijing Chest Hospital
Intervention: Contezolid(drug)
Enrollment: 24 enrolled
Eligibility: All sexes
Timeline: 2024 – 2025

Study locations (1)

Beijing chest hospital affiliated to Capital medical university, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, Beijing Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06811025 on ClinicalTrials.gov

Other trials for Central nervous system tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Central nervous system tuberculosis →

← Back to all trials